Category: Asbestos Exposure
Mother’s Diagnosis Reminds of Danger of Environmental Exposure to Asbestos
A mother of three children said her terminal cancer was caused by exposure to asbestos on the playground when she was a child. Asbestos causes cancer in humans including lung cancer and mesothelioma, a cancer of the lining of the lungs.
Penny Garner, 45, who lives in Manchester, England, was diagnosed with lung cancer caused by asbestos 18 months ago after suffering chest pains and initially being misdiagnosed with a pulled chest muscle and then pneumonia. According to the Manchester Evening News, Garner’s doctors eventually identified the cancer and asked her when she had worked with asbestos.
She recalled in a newspaper article spending playtimes while a primary school student in the 1970s watching builders demolish the historic Seedley baths next to the school, after asbestos was discovered in them. Garner said it was terrifying that she could develop a serious disease from playing in the school yard.
Garner said while her condition is stable at present, she has been told that her illness is terminal and is living in limbo between the tests she has to have every two months. The former seamstress said she tried to carry on a normal routine as much as possible for her children, but is very difficult.
Penny Garner’s tragic story underscores the fact that people may develop mesothelioma and lung cancer as a result of exposure to asbestos fibers in the surrounding environment. And while most people diagnosed with asbestos disease are older workers and veterans, young people also may develop the disease.
Workplace exposure to asbestos is more common than environmental exposure. But families of asbestos workers and people exposed to asbestos in the environment are susceptible to mesothelioma and asbestos disease.
According to the National Cancer Institute, while it’s clear that health risks from asbestos exposure increase with longer duration of exposure, researchers have found asbestos-related diseases in individuals with only brief exposure to asbestos. Asbestos disease has a long latency period of 20 years to 40 years before cancer symptoms appear.
Get to know more about mesothelioma and how you can deal with it.
Patient Has Lived Disease Free Since Diagnosis of Malignant Pleural Mesothelioma
Doctors in Japan describe the unusual case of a long-term mesothelioma survivor who was treated with chemotherapy and hyperthermia.
In the Dec. 28 online issue of the Journal of Medical Case Reports, doctors at Gunma University School of Medicine in Japan detail the case of a 61-year-old man who has lived disease free for seven years after being diagnosed with malignant pleural mesothelioma. Pleural mesothelioma is a cancer of the lining of the chest cavity caused by exposure to asbestos. The cancer typically has a high mortality rate.
The man was experiencing chest pain and had a history of exposure to asbestos for approximately five years. A CT scan showed a thickening of the pleural lining of his chest. It also revealed tumors had invaded the wall of patient’s chest. Doctors diagnosed the patient with stage 3 malignant pleural mesothelioma based on blood test results and an examination.
The patient was eligible for surgery, but refused to undergo surgery or receive radiation treatment. So doctors administered systemic chemotherapy with hyperthermia, which the medical center used as treatment for patients with inoperable lung cancer. The chemotherapy drugs consisted of cisplatin and irinotecan, an antitumor drug that interferes with how cancer cells multiply.
Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures of up to 113 degrees. According to the National Cancer Institute, high temperatures can damage and kill cancer cells, causing tumors to shrink, usually with minimal injury to normal tissues. Hyperthermia also may enhance the effectiveness of some anti-cancer drugs. It’s usually used in conjunction with other cancer treatments. The patient underwent hyperthermia treatment immediately after receiving the irinotecan drugs.
A month after the first cycle of mesothelioma treatment, the patient had a follow-up CT scan which showed that the thickening of the pleural lining had disappeared. He still has some fluid in his chest cavity, which is common for mesothelioma patients. The patient underwent three sessions of hyperthermia and a single course of chemotherapy. Another CT scan six years after the end of treatment revealed no evidence of a return of the cancer.
Patients diagnosed with mesothelioma typically have a poor prognosis because of the cancer’s resistance to conventional treatments. Many survive less than two years. As a result, medical researchers continue seeking more effective treatments for mesothelioma to extend the lives of patients and improve their quality of life.
The authors of the case report conclude that hyperthermia and chemotherapy may be a new and safe therapeutic option for treatment of pleural mesothelioma. They say that additional clinical studies of the combination of chemotherapy and hyperthermia are needed to further assess the effectiveness of the therapy.
New Report: Incidence Of Mesothelioma More Than Doubled in Ireland Since 1990s
A new report on cancer trends by Ireland’s National Cancer Registry says the incidence of mesothelioma among men in Ireland has doubled since the 1990s and will continue soaring during the next decade. Mesothelioma is a cancer of the thin lining of the lungs and abdominal cavity.
Despite large year-to-year variations in the number of cases of pleural mesothelioma diagnosed on the Emerald Isle, the report says the incidence of pleural mesothelioma among men has more than doubled since 1994 from an average of 13 cases per year in 1994-96 to 36 cases in 2009. The researchers project the number of cases will increase to 68 cases of mesothelioma per year in men by 2020.
Most people encountered asbestos on the job. Approximately 97 percent of men and 82 percent of women diagnosed with mesothelioma inhaled asbestos fibers in a workplace.
Pleural mesothelioma develops in the lining of the chest cavity and is by far the most common form of the disease. Ninety four percent of the cases of mesothelioma in men and 75 percent of the cases in women in Ireland were malignant pleural mesothelioma.
Mesothelioma is largely linked to chronic exposure to asbestos in male-dominated jobs. Of the mesothelioma patients in Ireland whose occupations were documented, half were construction workers, electricians, carpenters, metal workers and woodworkers. More than five times as many men as women were diagnosed with mesothelioma. Mesothelioma is more prevalent among construction workers and workers in occupations exposed to asbestos in the United States as well.
While asbestos was used heavily in the United States starting during 1940s, asbestos was mostly used in Ireland from the 1960s to the 1980s. Ireland began phasing out the use of asbestos in the 1990s and its use was generally banned under European Union regulations in 2000. Because of the long latency period of 20 to 40 years between asbestos exposure and appearance of mesothelioma, researchers in Ireland project the incidence of mesothelioma will peak in 2020.
The majority of pleural mesothelioma patients were between 60 to 80 years of age when diagnosed. Chemotherapy has become an increasingly common form of treatment for mesothelioma. Almost 60 percent of male and female patients with mesothelioma received chemotherapy from 2005 to 2010.
Yet, pleural mesothelioma has a poor prognosis. More than 70 percent of mesothelioma patients enrolled in the cancer registray since 1994 died within one year of diagnosis.
For Patients With Mesothelioma, Thirteen Relevant Facts About Asbestos Disease in 2013
A group of nine doctors from New York University, the University of Hawaii and other research universities who specialize in treating mesothelioma patients discussed facts, theories and myths about mesothelioma in an article in the Journal of Cell Physiology, a peer-reviewed scientific journal. Their findings, made available online in January 2013, are well worth revisiting at the outset of the new year.
Here are 13 bold points from the article:
- More than 20 million people in the United States are at risk of developing malignant mesothelioma due to asbestos exposure.
- The duration and intensity of an individual’s exposure to asbestos are important variables affecting the likelihood of development of asbestos disease.
- All studies agree that the incidence of mesothelioma among men has continued to rise during the last five decades, while the incidence among women has remained relatively flat. More than 100,000 U.S. citizens are expected to die of mesothelioma during the next 40 years.
- The development of mesothelioma is related to the chronic inflammatory process caused by the presence of microscopic asbestos fibers in the chest cavity.
- Development of malignant mesothelioma has been associated with commercial use of asbestos in the early and mid 20th century. Prior to the 1950s, malignant mesothelioma tumors were extremely rare.
- Today, malignant mesothelioma is responsible for approximately 2,500 to 3,000 deaths per year in the United States and approximately 5,000 deaths in Western Europe.
- It’s a myth that asbestos has been banned in commercial products in the United States. Countries in the European Union have banned asbestos use, but not the U.S. The continued import of products containing asbestos in the U.S. and potential exposure to asbestos in place means workers exposed to the mineral fibers will continue to be at risk of developing mesothelioma.
- It’s a myth that malignant mesothelioma will soon disappear because of reduced use of the product. The rate of malignant mesothelioma has remained constant since 1994 and is increasing in some countries.
- It’s a myth that mesothelioma is a slow growing tumor. Mesothelioma grows aggressively once the cancer develops and most likely produces clinical symptoms within a few years. There is a long latency period of 20 to 70 years between initial exposure to asbestos fibers and the development of mesothelioma. The distinction is important. The latency period appears to be influenced by the amount of exposure. Workers in trades with higher exposure to asbestos may have shorter latency periods before the cancer develops.
- Due to the long latency period, researchers estimate that mesothelioma mortality rates will continue to increase 5 to 10 percent per year in most industrialized countries for the next two to three decades despite efforts to get rid of asbestos. In the U.S, the number of mesothelioma deaths is likely to exceed 3,000 per year. Approximately 20 to 25 percent of deaths due to mesothelioma in the U.S. are misattributed to other causes.
- A mesothelioma patient’s survival is influenced by the stage of the cancer upon treatment.
- Stage I is the localized cancer while Stage IV describes advanced cancer that has spread beyond the point of origin. Among 663 patients who underwent surgical procedures for mesothelioma from the 1990 through 2006, the median survival was:
- Stage I mesothelioma — 38 months median survival
- Stage II mesothelioma—19 months
- Stage III mesothelioma—11 months
- Stage IV mesothelioma—7 months
- It’s expected that development of reliable blood tests that can lead to earlier detection of mesothelioma before it has advanced to stage III or IV will increase the percentage of patients who are candidates for surgery and increase overall survival.
New Drugs Rally Immune System to Fight Cancer
For many years, cancer researchers have questioned why the immune system doesn’t react to cancer cells as invaders and attack them. A deepening understanding of genetic drivers of disease reveals that the cancerous tumors take over the brake control on the immune system.
A recent article in The Wall Street Journal underscores the advances being made in new drugs that release the brake and allow the immune system to fight various forms of cancer, including cancers associated with asbestos exposure.
For Tom Stutz, a 72-year-old retired lawyer in California, taking each breath was a struggle and even doing simple tasks such as eating a meal required help as cancer advanced in his lungs and liver. In April, Stutz, who was confined to a wheelchair, began taking an experimental drug known as MK-3475 that reactivated his immune system to fight cancer. Today, Mr. Stutz is walking 3.5 miles a day, has parked his wheelchair, and reports feeling terrific, according to The Wall Street Journal article about innovative medical treatments. Doctors informed Mr. Stutz in the fall that his tumors had shrunk by 65 percent.
MK-3475, which has not yet been approved by the U.S. Food and Drug Administration, is under development by Merck & Co. It is among a class of drugs known as PD-1 inhibitors. The drugs disrupt the ability of cancer to hijack the immune system and boosts the immune response to certain cancers. In testing the drug on patients with metastatic melanoma, researchers reported in November that about 9 percent of patients who took the drug has no observable cancer after 12 weeks while half of the study participants had tumor shrinkage.
Merck is currently recruiting cancer patients to participate in clinical trials to study the safety and tolerability of the drug to treat several forms of cancer including non-small cell lung cancer, one of the cancers associated with asbestos exposure. You can find contact information about the clinical trial here.
Free Mesothelioma Patient & Treatment Guide
We’d like to offer you our in-depth guide, “A Patient’s Guide to Mesothelioma,” absolutely free of charge.
It contains a wealth of information and resources to help you better understand the condition, choose (and afford) appropriate treatment, and exercise your legal right to compensation.
Download Now